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Abstract 
Background: The efficacy of Lactobacillus paracasei NCC 2461 in modulating allergic rhinitis was previously evalu-
ated in two exploratory clinical studies. Oral administration with NCC 2461 reduced specific subjective symptoms 
following nasal provocation tests with controlled grass pollen allergen concentrations. Our aim was to confirm the 
anti-allergic effect of NCC 2461 in grass pollen allergic subjects exposed to natural doses of allergens during the pol-
len season.
Findings: A double-blind, randomized, placebo-controlled, parallel study was conducted with 131 grass pollen 
allergic subjects from May to July 2012 in concomitance with the pollen season in Berlin. NCC 2461 or placebo was 
administered daily for an 8-week period to adult subjects with clinical history of allergic rhinitis to grass pollen, posi-
tive skin prick test and IgE to grass pollen. During the 8 weeks, symptoms and quality of life questionnaires were 
filled out, and plasma was collected for IgE analysis at screening and at the end of the intervention. All subjects were 
included within a 5-day interval, ensuring exposure to similar air pollen counts for each individual during the trial 
period. The results obtained show that symptoms increased with pollen loads, confirming a natural exposure to the 
allergen and presence of pollen-induced allergic rhinitis in the subjects. However, no significant differences were 
observed in allergic rhinitis symptoms scores, quality of life, or specific IgE levels between subjects receiving NCC 
2461 as compared to placebo administration.
Conclusion: In contrast to previous findings, oral administration of NCC 2461 did not show a beneficial effect on 
allergic rhinitis in a field trial. The influence of study design, allergen exposure and intervention window on the effi-
cacy of NCC 2461 in modulating respiratory allergy should be further evaluated.
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Findings
Probiotics and allergic rhinitis
 Allergic rhinitis to grass pollen affects around 20 % of the 
population in Europe, USA and Oceania and is character-
ized by nasal and ocular symptoms, such as nasal conges-
tion or watery eyes, which significantly impact the quality 
of life of allergic subjects [1–3]. In addition to standard 
medications, such as anti-histamines and corticoster-
oids, aiming at the management of allergic rhinitis symp-
toms, nutritional interventions with probiotics have been 
explored in clinical trials [4, 5]. Oral intake of probiot-
ics, in particular lactobacilli and bifidobacteria, has been 
shown to modulate allergic immune responses as well as 
to have a significant impact on symptoms reduction [6–
11]. Administration of Lactobacillus paracasei NCC 2461 
significantly decreased subjective nasal congestions in 
subjects with a medical history of allergic rhinitis to grass 
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(NPT) in a proof-of-concept study performed outside 
of the pollen season [12]. In a second study, NCC 2461 
improved NPT-induced nasal pruritus in grass pollen 
allergic subjects when compared to a different probiotic 
blend; the effect observed was comparable to the symp-
toms reduction obtained with an anti-allergic drug tested 
with the same NPT protocol [13]. In line with these 
results, we aimed to further demonstrate the efficacy of 
NCC 2461 in a clinical trial performed during the grass 
pollen season, in which subjects are exposed to natural 
doses of allergens.
Study design and outcomes
The study was designed as a randomized, double 
blind, placebo-controlled, parallel trial, and was per-
formed between May and July 2012 at Charité Research 
Organisation GmBh in Berlin (ClinicalTrials.gov: 
NCT01653652). One hundred and thirty-one volunteers 
were enrolled on the basis of the following inclusion cri-
teria: 18–65 years of age, body mass index in the range 
of 19–32  kg/m2, established allergic rhinitis to grass 
pollen for more than 2 years, positive skin prick test to 
grass pollen and grass pollen-specific IgE (≥0.35 kU/L). 
Exclusion criteria comprised pregnancy, infection or 
antibiotic intake at time of enrollment, asthma and other 
chronic disorders, and the use of systemic corticoster-
oids prior to randomization. Enrollment was completed 
within 5  days to ensure that all subjects were exposed 
to natural airborne pollen during the same period of 
the pollen season. The treatment consisted of daily oral 
intake of 5  g of placebo (maltodextrin) or a probiotic 
blend containing 5 × 109 CFU NCC 2461 over a period 
of 8 weeks. Placebo and probiotics were packed in pow-
der form in single sachets for each daily dose. Study 
design and CONSORT flow diagram are outlined in 
Additional file 1: Figure S1.
 The primary objective of the study was to evaluate the 
efficacy of NCC 2461 in mitigating grass pollen-induced 
allergic rhinitis symptoms by comparing daily total nasal 
symptom score (TNSS) over 8  weeks (from V1–V3) 
between the probiotic and the placebo group. TNSS as 
well as total ocular symptom score (TOSS, both described 
in Additional file  1: Questionnaires and plasma analy-
sis) were recorded daily by the subjects with the help of 
an electronic patient reported outcome (ePRO) device. 
On a weekly basis, subjects were asked to fill a validated 
quality of life questionnaire specific for allergic rhinitis, 
the mini Rhinoconjuctivitis Quality of Life Questionnaire 
(miniRQLQ) [14]. Subjects were allowed to take any anti-
allergic medication at their discretion, and the type and 
dose of each drug was recorded. Decrease in medication 
intake through probiotic intervention was a secondary 
objective of the study, and the outcome measure was the 
weekly rescue medication score questionnaire (Additional 
file 1: Questionnaires and plasma analysis). Of note, TNSS 
was adjusted for medication score at V1, to avoid possible 
biases on symptoms of the basal status of the subjects.
To evaluate the effect of probiotic administration on 
grass pollen-specific IgE, serum was collected at screen-
ing and at V3 and results compared between NCC 2461 
and placebo group.
The primary statistical analysis was carried out on the 
change from baseline TNSS scores using a Linear Mixed 
Model, where treatment group, day of treatment and their 
interaction were considered as fixed effects and with sub-
ject number as a random effect to control for within sub-
ject variability. Secondary analyses were done in a similar 
fashion as the primary analysis. A summary of inclusion 
and exclusion criteria, primary and secondary outcomes, 
as well as methods can be found in the Additional file 1.
Efficacy of L. paracasei NCC 2461
Baseline demographics are shown in Additional file  1: 
Table S1. Sixty-eight subjects were assigned to the pla-
cebo group, sixty-three to the NCC 2461 group, and all 
one hundred and thirty-one subjects were included in the 
intention-to-treat (ITT) analysis. Of note, results of the 
per-protocol analysis did not differ from ITT. One sub-
ject receiving placebo withdrew from the study due to a 
bacterial infection unrelated to product intake.
Analysis of grass pollen concentrations in Berlin dur-
ing the 2012 season indicated that at enrollment, begin-
ning of May, pollen counts were still low (Fig. 1a). Further 
analysis highlighted a positive correlation between pollen 
counts and the primary outcome TNSS confirming the 
presence of grass pollen-induced allergic rhinitis mani-
festations in line with the clinical history of the study 
subjects. The maximum values for both pollen and symp-
tom measures were observed 20 days after the start of the 
trial. Treatment with NCC 2461 however did not have an 
effect on symptoms, as no significant differences in TNSS 
were observed between probiotic and placebo at any time 
point (Fig.  1b). Individual symptoms scores were also 
comparable between groups (Additional file  1: Figure 
S2). In line with these results, NCC 2461 administration 
did not show an effect on quality of life over the 8-week 
period (Fig.  2), and grass pollen-specific IgE in plasma 
did not differ between placebo and probiotic group at 
both time points assessed (Additional file  1: Figure S3). 
Total and individual ocular symptoms were also com-
parable (data not shown). Subjects were allowed to take 
anti-allergic medication whenever they felt the need; the 
intake was not influenced by the probiotics, as no statisti-
cally significant differences in frequencies were observed 
when compared to placebo at any of the time points 
(Table 1).  
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Probiotic administration was considered safe as no 
serious adverse event was recorded during the trial. 
Subjects receiving NCC 2461 reported fewer episodes 
of nasopharyngitis, however the frequency of minor 
adverse events was not a trial outcome and was therefore 
not considered in the statistical analysis.
Discussion
Prior to this study, the effect of NCC 2461 in modulat-
ing grass pollen allergic rhinitis was evaluated in two 
exploratory studies, outside the pollen season in nasal 
provocation test settings [12, 13]. Results of these trials 
suggested a role of NCC 2461 in immune regulation, as 
cytokine expression by peripheral blood mononuclear 
cells cultures [12] or in nasal secretions [13] was sig-
nificantly different when compared to a placebo [12] or 
a different probiotic blend [13]. In addition, both stud-
ies showed that NCC 2461 administration might affect 
distinct subjective symptoms of allergic rhinitis, namely 
congestion [12] and pruritus [13]. In contrast, the results 
from the study presented in this manuscript indicate no 
effect of NCC 2461 in modulating TNSS, TOSS, nor any 
Fig. 1 TNSS is comparable between placebo and NCC 2461 administration. a The correlation between daily grass pollen counts during the trial 
period and daily TNSS values is represented; both parameters reached maximum values in the last week of May, 20 days after the start of the trial, 
and no significant differences were observed between the study groups. The solid and broken curves represent Loess local smoothing method (with 
95 % level of confidence) applied to TNSS scores of placebo and NCC 2461 groups, respectively, in order to summarize daily symptom scores. The 
volatile line refers to daily pollen counts with corresponding levels (referring to the right vertical axis). Pollen data were provided by the Geowis-
senschaften Institut für Meteorologie of the Freie Universität in Berlin. b Mean TNSS score for each week of each subject was calculated; boxplots 
represent the weekly mean for the two study groups
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of the symptoms considered individually. The discrep-
ancy in outcomes between the different studies using 
NCC 2461 might be explained by the difference in study 
design between the previous trials and the current one, 
and the different approaches taken to expose subjects to 
the allergen in order to induce allergic rhinitis symptoms.
Fig. 2 NCC 2461 administration does not impact quality of life. Similar to TNSS, no statistically significant differences were observed between probi-
otic and placebo group at any time point. Boxplots for weekly mean miniRQLQ are shown
Table 1 Medication score comparison between NCC 2461 and placebo group
Numbers in brackets are frequencies
Placebo
Week 0 (N = 68) 1 (N = 68) 2 (N = 68) 3 (N = 68) 4 (N = 68) 5 (N = 68) 6 (N = 67) 7 (N = 67) 8 (N = 41)
Medication score
 0 63 % (43) 68 % (46) 59 % (40) 54 % (37) 63 % (43) 65 % (44) 63 % (42) 72 % (48) 66 % (27)
 1 32 % (22) 29 % (20) 37 % (25) 38 % (26) 34 % (23) 31 % (21) 31 % (21) 25 % (17) 29 % (12)
 2 1 % (1) 1 % (1) 1 % (1) 3 % (2) 1 % (1) 3 % (2) 4 % (3) 1 % (1) 2 % (1)
 3 3 % (2) 1 % (1) 3 % (2) 4 % (3) 1 % (1) 1 % (1) 1 % (1) 1 % (1) 2 % (1)
NCC 2461
Week 0 (N = 63) 1 (N = 63) 2 (N = 63) 3 (N = 63) 4 (N = 63) 5 (N = 63) 6 (N = 63) 7 (N = 63) 8 (N = 35)
Medication score
 0 81 % (51) 84 % (53) 63 % (40) 63 % (40) 65 % (41) 63 % (40) 70 % (44) 70 % (44) 74 % (26)
 1 19 % (12) 16 % (10) 35 % (22) 32 % (20) 33 % (21) 35 % (22) 29 % (18) 29 % (18) 26 % (9)
 2 0 % (0) 0 % (0) 0 % (0) 3 % (2) 0 % (0) 0 % (0) 0 % (0) 0 % (0) 0 % (0)
 3 0 % (0) 0 % (0) 2 % (1) 2 % (1) 2 % (1) 2 % (1) 2 % (1) 2 % (1) 0 % (0)
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Wassenberg et al. [12] as well as Perrin et al. [13] evalu-
ated the effect of NCC 2461 administration on symp-
toms’ reduction following a NPT in which all subjects 
were exposed to the same increasing doses of grass pol-
len at each challenge; both trials were performed outside 
of the pollen season. In our current in-season trial, expo-
sure of each subject to grass pollen occurred in a natu-
ral and obviously non-controlled manner, and allergen 
doses might have varied considerably over time as well as 
within the whole study population. In addition to pollen 
counts, the country in which the study was performed, as 
well as other environmental factors such as climate and 
air pollution could also influence the results of a trial 
conducted during the pollen season [15, 16].
The difference in outcome measures between stud-
ies should also be considered; in the previous trials sub-
jective symptoms (pruritus and nasal congestion) were 
measured with visual analogue scales, and immunologi-
cal parameters such as cytokine secretion and IgG4 were 
not measured in the study performed in Berlin. Also, the 
dose we used here (5 × 109 CFU/day) was slightly lower 
than in previous NCC 2461 studies due to the different 
format used; however, it was still in the range of common 
doses of probiotics tested in clinical trials [6, 9, 17, 18].
Another important variable to take into account is the 
use of anti-allergic medication by the subjects. Intake was 
recorded and compared between probiotic and placebo 
group through the rescue medication score question-
naire; no significant differences could be observed. On 
the other hand, there was no adjustment of the primary 
endpoint TNSS for covariates such as anti-allergic medi-
cation intake at any time point except for V1, to correct 
for basal level. For this reason we cannot exclude that the 
single consumption of anti-histamines or corticosteroids 
by the subjects had an influence on the reporting of their 
symptoms. In this case, a primary outcome comprising 
both symptoms and medication intake score results could 
have been a relevant approach [19]. Moreover, allergic 
rhinitis to other aeroallergens such as house dust mite or 
pet dander was not an exclusion criterion, as the major-
ity of subjects suffering from allergic airway diseases are 
polysensitized; thus, reactions other than to grass pollen 
could have had an impact on TNSS and medication score 
as well.
Our objective was to evaluate the role of NCC 2461 in 
conditions as near as possible to real-life, namely with 
natural exposure to allergens and with medication intake 
at subject’s discretion. It can be speculated however that 
the effect of the intervention is more difficult to detect 
in these settings. Of note, in three clinical trials in which 
probiotic administration was associated to the con-
trolled intake of anti-allergic drugs such as loratadine or 
levocetirizine, a significant impact on symptoms reduc-
tion or quality of life improvement on top of the medi-
cation was observed [6, 18, 20]. The trials described in 
Costa et  al. and Lue et  al. were performed in subjects 
with moderate-to-severe rhinitis according to ARIA clas-
sification; significant clinical differences might be better 
detectable in this population as compared to mild allergic 
rhinitis [21, 22]. In our trial, we did not differentiate sub-
jects on the basis of ARIA classification.
Importantly, in contrast to our earlier NCC 2461 trials, 
in which probiotics were administered for 4 weeks prior 
to pollen challenge by NPT [12, 13], probiotic intake in 
the study presented here occurred at the same time as 
the exposure to the allergen. In fact in most of previ-
ously published studies in which probiotics had a posi-
tive impact on allergic rhinitis to pollen (grass, birch or 
Japanese cedar), the intervention started weeks before 
season start or nasal challenge [11–13, 17, 22–25]. On 
the other hand, in the only other reported trial that had 
a similar experimental design as the current one, i.e., 
parallel, 8-week long, with similar outcomes and most 
importantly run at the peak of the pollen season, we 
could show that administration of Bifidobacterium lac-
tis NCC 2818 did significantly reduce TNSS in allergic 
subjects [9]. The mechanisms of action of probiotics, 
including NCC 2461, are not entirely elucidated and can 
vary according to the strain used; the same is true for 
the appropriate doses and intervention windows needed 
to observe a beneficial effect [21, 22, 26–31]. It can be 
speculated that some probiotics have a higher impact on 
allergic responses by priming the immune system prior 
to allergen challenge; this could be the case of NCC 
2461. Different strains might conversely be more effec-
tive in symptoms management when the allergy reaction 
is already ongoing. The immune-regulatory properties 
and mechanisms of action of specific probiotic strains 
are thus worth being carefully investigated; study design 
and intervention window of future efficacy trials should 
also be aligned accordingly.
Finally, we believe more evidence is needed in closer-
to-real-life, field-trials settings to conclude on the most 
appropriate probiotic intervention. Taken together how-
ever, our NCC 2461 trials and other previously published 
observations suggest that starting probiotic intake before 
the pollen season as well as administration together 
with a controlled medication regimen may be the pref-
erable strategy for the management of seasonal allergic 
manifestations.
Additional file
Additional file 1. Population, protocols and supplementary figures.
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